Efficacy and Safety of Azimilide in the Prophylactic Treatment of Patients With Atrial Fibrillation.

NCT ID: NCT00035464

Last Updated: 2011-10-03

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

431 participants

Study Classification

INTERVENTIONAL

Study Start Date

2000-12-31

Study Completion Date

2004-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Atrial fibrillation (an abnormal rhythm in the upper chamber of the heart) is a common supraventricular arrhythmia (a type of abnormal heart rhythm) for which antiarrhythmic therapy is often prescribed. The primary goals of therapy are to maintain sinus rhythm (normal heart rhythm) and to reduce the occurrence of episodes of atrial fibrillation. Azimilide may have an effect on increasing the time to first recurrence of symptomatic atrial fibrillation or atrial flutter and symptomatic paroxysmal supraventricular tachycardia (other types of abnormal heart rhythms).

This double-blind, placebo-controlled study is designed to evaluate the efficacy and safety of azimilide compared with placebo in prolonging the time to the first symptomatic arrhythmia recurrence in patients with a history of atrial fibrillation and congestive heart failure and/or ischemic heart disease) and those without these conditions. Once this phase of the study is completed, a second phase with a different study design will be conducted. The second phase is an open-label, follow-up phase. The follow-up phase of the study is designed to evaluate the long-term efficacy and safety of a daily oral dose of azimilide in patients who complete the double-blind, placebo-controlled phase of this study.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Atrial Fibrillation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

Placebo tablets

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

placebo tablets, twice a day for 6 months

2

125 mg azimilide tablets

Group Type EXPERIMENTAL

Azimilide Dihydrochloride

Intervention Type DRUG

125 mg azimilide tablets, twice a day for 6 months

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Azimilide Dihydrochloride

125 mg azimilide tablets, twice a day for 6 months

Intervention Type DRUG

Placebo

placebo tablets, twice a day for 6 months

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* History of symptomatic atrial fibrillation that significantly disrupts the patient's customary daily living activities
* History of congestive heart failure and/or ischemic heart disease
* Sinus rhythm (normal heart rhythm) upon entry to the 30 day screening period for the study
* At least one episode of symptomatic atrial fibrillation during the screening period, with a spontaneous return to sinus rhythm.
* Sinus rhythm immediately prior to dosing

Exclusion Criteria

* Previously unsuccessful cardioversions within 60 days of screening period
* Failed to respond to any Class III antiarrhythmic drugs
* Qualifying arrhythmia due to acute reversible illness, acute myocardial infarction, and/or cardiac or thoracic surgery within one month prior to randomization
* Previously in an azimilide study
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Forest Laboratories

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Procter & Gamble Pharmaceuticals

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Martin Phillips, MD

Role: STUDY_DIRECTOR

Procter and Gamble

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Cardiovascular Assoc. PC

Birmingham, Alabama, United States

Site Status

The Heart Group, PC

Mobile, Alabama, United States

Site Status

Southern Arizona VA Health Care System, Section of Cardiology (1-111C)

Tucson, Arizona, United States

Site Status

University Medical Center

Tucson, Arizona, United States

Site Status

University of Arkansas Medical Center

Little Rock, Arkansas, United States

Site Status

Cardiovascular Associates of Penisula

Burlingame, California, United States

Site Status

Capitol Interventional Cardiology

Carmichael, California, United States

Site Status

VA Central California Health Care System

Fresno, California, United States

Site Status

Valley Research

Fresno, California, United States

Site Status

Grass Valley Cardiology

Grass Valley, California, United States

Site Status

San Diego Cardiovascular Associates

La Jolla, California, United States

Site Status

Good Samaritan Hospital

Los Angeles, California, United States

Site Status

LAC+USC Medical Center

Los Angeles, California, United States

Site Status

Cardiology Section, West Los Angeles VA Hospital

Los Angeles, California, United States

Site Status

Merced Heart Associates

Merced, California, United States

Site Status

Sutter Gould Medical Foundation

Modesto, California, United States

Site Status

ARI Clinical Trials

Redondo Beach, California, United States

Site Status

Regional Cardiology Assoc.

Sacramento, California, United States

Site Status

Sacramento Heart and Vascular Medical Associates

Sacramento, California, United States

Site Status

Cardiology Associates

San Diego, California, United States

Site Status

Aurora Denver Cardiology

Aurora, Colorado, United States

Site Status

Western Cardiology Assoc.

Denver, Colorado, United States

Site Status

Hartford Hospital

Hartford, Connecticut, United States

Site Status

The George Washington University MFA

Washington D.C., District of Columbia, United States

Site Status

Cardiology Consultants

Daytona Beach, Florida, United States

Site Status

C/O Research Office Attn: Cardiovascular Research Dept.

Fort Lauderdale, Florida, United States

Site Status

SW Florida Heart Group/Health Park Medical Center

Fort Myers, Florida, United States

Site Status

Jacksonville Center for Clinical Research

Jacksonville, Florida, United States

Site Status

Watson Clinic, LLP

Lakeland, Florida, United States

Site Status

Khalid Hassan Sheikh 80 Fontenberry Road

Merritt Island, Florida, United States

Site Status

Florida Cardiology

Orlando, Florida, United States

Site Status

Cardiology Research Assiocates

Ormond Beach, Florida, United States

Site Status

VA Medical Center

Decatur, Georgia, United States

Site Status

Mount Sinal Hospital Medical Center

Chicago, Illinois, United States

Site Status

Elgin Cardiology Associates

Elgin, Illinois, United States

Site Status

Illinois Heart & Lung Research Center, SC

Normal, Illinois, United States

Site Status

The Center for Advanced Cardiology

Park Ridge, Illinois, United States

Site Status

Heart Center Medical Group

Fort Wayne, Indiana, United States

Site Status

The Care Group

Indianapolis, Indiana, United States

Site Status

Professional Research Network of Kansas

Wichita, Kansas, United States

Site Status

University of Louisville-Cardiology

Louisville, Kentucky, United States

Site Status

Louisville Cardiology Medical Group, P.S.C

Louisville, Kentucky, United States

Site Status

Cardiovascular Institute of the South

Houma, Louisiana, United States

Site Status

Richard Gilmore, MD 501 S Ryan Street

Lake Charles, Louisiana, United States

Site Status

Cardiovascular of the South

Morgan City, Louisiana, United States

Site Status

Cardiovascular Institute of the South

New Iberia, Louisiana, United States

Site Status

Tulane University

New Orleans, Louisiana, United States

Site Status

Medical Research Institute

Slidell, Louisiana, United States

Site Status

Cardiovascular Institute of the South

Thibodaux, Louisiana, United States

Site Status

Maine Medical Center

Portland, Maine, United States

Site Status

Boston Medical Center

Boston, Massachusetts, United States

Site Status

University of Massachusett

Worcester, Massachusetts, United States

Site Status

Thoracic & Cardiovascular Healthcare Foundation

Lansing, Michigan, United States

Site Status

Nisus Research

Petoskey, Michigan, United States

Site Status

Riverside Osteopathic Hospital

Trenton, Michigan, United States

Site Status

Regional Heart Center

Duluth, Minnesota, United States

Site Status

Fairview Range Regional Health Services

Hibbing, Minnesota, United States

Site Status

VA Medical Center Therapeutic Section

Minneapolis, Minnesota, United States

Site Status

St. Patrick Hosp/Western Mt. Clinic Cardiology

Missoula, Montana, United States

Site Status

Internal Medical Associates

Grand Island, Nebraska, United States

Site Status

William Olney, MD 21 Whitehall Rd, Suite 200

Rochester, New Hampshire, United States

Site Status

Cardiology & Int. Medicine

Williamsville, New York, United States

Site Status

Duke Medical Center

Durham, North Carolina, United States

Site Status

Altru Health System Research Center

Grand Forks, North Dakota, United States

Site Status

Lindner Clinical Trial Ctr.

Cincinnati, Ohio, United States

Site Status

University Hospitals of Cleveland

Cleveland, Ohio, United States

Site Status

MidWest Cardiology Research Foundation

Columbus, Ohio, United States

Site Status

Oklahoma Foundation for Cardiovascular Research

Oklahoma City, Oklahoma, United States

Site Status

Hillsboro Cardiology

Hillsboro, Oregon, United States

Site Status

Oregon Health Sciences University

Portland, Oregon, United States

Site Status

Heart Care Group PC

Allentown, Pennsylvania, United States

Site Status

Tri-State Medical Group Cardiology

Beaver, Pennsylvania, United States

Site Status

Milton S. Hershey Medical Center

Hershey, Pennsylvania, United States

Site Status

The Pavillion

Jenkintown, Pennsylvania, United States

Site Status

UPHS/Presbyterian Medical Center

Philadelphia, Pennsylvania, United States

Site Status

Cardiovascular and Critical Care Associates, P.C.

Pittsburgh, Pennsylvania, United States

Site Status

Charleston Cardiology

Charleston, South Carolina, United States

Site Status

Stern Cardiovascular Center Research Department

Memphis, Tennessee, United States

Site Status

UT Southwestern Medical Center

Dallas, Texas, United States

Site Status

Methodist Hospital

Houston, Texas, United States

Site Status

Heart and Vascular Inst. of Texas, PA

San Antonio, Texas, United States

Site Status

MedSource, Inc

Chesapeake, Virginia, United States

Site Status

Riverside Regional Medical Center

Newport News, Virginia, United States

Site Status

Daniel Gottlieb, MD 16259 Sylvester Road SW, Suite 401

Seattle, Washington, United States

Site Status

Beloit Clinic, SC

Beloit, Wisconsin, United States

Site Status

Dean/Riverview Clinic

Janesville, Wisconsin, United States

Site Status

University of Wisconsin Madison

Madison, Wisconsin, United States

Site Status

Marshfield Clinic

Marshfield, Wisconsin, United States

Site Status

Heart Health Institute

Calgary, Alberta, Canada

Site Status

Heart Health Research Center

Calgary, Alberta, Canada

Site Status

University of Calgary

Calgary, Alberta, Canada

Site Status

Cardiology Research St. Paul's Hospital

Vancouver, British Columbia, Canada

Site Status

Neureka Research Corporation

Greater Sudbury, Ontario, Canada

Site Status

Hamilton Health Science Corp.

Hamilton, Ontario, Canada

Site Status

Cardiac Investigation Unit

London, Ontario, Canada

Site Status

Niagara Health System Greater Niagara General Hospital

Niagara Falls, Ontario, Canada

Site Status

University of Ottawa Heart Institute

Ottawa, Ontario, Canada

Site Status

St. Michael's Hospital

Toronto, Ontario, Canada

Site Status

Montreal Heart Institute

Montreal, Quebec, Canada

Site Status

Recharche Cardiologie

Montreal, Quebec, Canada

Site Status

Chum Hotel Dieu

Montreal, Quebec, Canada

Site Status

Hospital Sacre-Soeur de Montreal

Montreal, Quebec, Canada

Site Status

Quebec Heart Institute

Sainte-Foy, Quebec, Canada

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Canada

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2000037

Identifier Type: -

Identifier Source: org_study_id